1. Introduction {#s1}
===============

The international Inflammatory Bowel Disease \[IBD\] Expert Alliance initiative served as a platform to define and support areas of best practice in IBD management. As part of the initiative, IBD specialists from Canada, the USA, Europe, Japan and New Zealand gathered for a series of meetings held in Calgary, Canada, and Tokyo, Japan, from 2012 to 2015 \[see [Appendix](#A1){ref-type="app"} for a full list of participants\]. The programme aimed to establish inter-regional sharing of best practice, communicating areas of clinical and technical expertise, and aligning specialist opinion behind common themes where joint working could improve outcomes for all patients with IBD. Two best practice charters---the 5S Principles and the 5C Concept---were generated through the programme. The aim of this article is to convey these charters to the wider gastroenterology community, highlighting their potential value towards improving IBD clinical practice and patient outcomes.

2. The 5S principles {#s2}
====================

The 5S Principles in IBD management were conceived during round-table group discussions at the inaugural IBD Expert Alliance meeting in Calgary, Canada, in 2012. They are based on Japan's 5S organisational methodology. This is a method initially applied in business environments to provide a structure for implementation of corporate programmes. It includes a series of identifiable steps, each building on its predecessor, to improve access to information and efficiency.^[@CIT0001]^ 5S engages individuals through highlighting and applying a set of agreed standards; therefore, it forms a good foundation to focus on continuous improvement. 5S can be applied across all sectors to achieve high-impact results, and has recently been extended from business to other industries, including education and health care.

The objective of the 5S Principles in IBD is to provide health care providers \[HCPs\] with key guidance for improving clinical practice based on best management approaches. The final 5S Principles in IBD were reached through group consensus and comprise the following: Stage the disease; Stratify patients; Set treatment goals; Select appropriate treatment; and Supervise therapy \[[Table 1](#T1){ref-type="table"}\]. Application of the 5S Principles in clinical practice was discussed in detail during subsequent Expert Alliance meetings to allow ongoing sharing of best practice approaches; the outputs are shared in this article.

###### 

The 5S Principles in IBD management.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Principle                      Implications in CD                                                                                                                                                        Implications in UC
  ------------------------------ ------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Stage the disease              • Define the location \[ileal, colonic, ileocolonic; perianal disease; upper GI involvement\]\                                                                            • Define the location \[proctitis, left-sided, extensive\]\
                                 • Define the duration \[early or late onset of disease\]\                                                                                                                 • Define the severity \[mild, moderate, severe, or ASUC\]\
                                 • Define the behaviour \[inflammatory, stricturing, or penetrating\]\                                                                                                     • Identify risk markers for disease course \[CRP, endoscopy, anaemia\]\
                                 • Exclude complications                                                                                                                                                   • Exclude complications\
                                                                                                                                                                                                           • Surveillance colonoscopy for UC-associated tumour, with best practice

  Stratify patients              Based on risk factors for a more aggressive disease course:\                                                                                                              Based on risk factors for a more aggressive disease course:\
                                 • Extensive small bowel disease\                                                                                                                                          • ASUC\
                                 • Severe upper GI disease\                                                                                                                                                • Steroid-refractory disease\
                                 • Severe rectal disease\                                                                                                                                                  • Thiopurine-refractory disease\
                                 • Patients with complex perianal disease\                                                                                                                                 • Surgery risk \[high stool frequency, high CRP, severe endoscopic lesions, histological inflammation, anaemia, low albumin, malnutrition\]
                                 • Patients with early stricturing / penetrating disease\                                                                                                                  
                                 • Patients with deep colonic ulcers                                                                                                                                       

  Set treatment goals            • Based on the time-bound treatment algorithm in IBD\                                                                                                                     • Based on the time-bound treatment algorithm in IBD\
                                 • Based on a treat-to-target approach\                                                                                                                                    • Based on a treat-to-target approach\
                                 • Resolution of clinical symptoms and inflammation, including mucosal healing, with normalisation of quality of life, tailored to the individual patient \[STRIDE\]^15^   • Resolution of clinical symptoms and inflammation, including mucosal healing, with normalisation of quality of life, tailored to the individual patient \[STRIDE\]^15^

  Select appropriate treatment   Based on treatment goals:\                                                                                                                                                Based on treatment goals:\
                                 • Tailored use of the current IBD drug armamentarium to deliver specific management goals and improve patient outcomes                                                    • Tailored use of the current IBD drug armamentarium to deliver specific management goals and improve patient outcomes

  Supervise therapy              • Use optimised, objective monitoring\                                                                                                                                    • Use optimised, objective monitoring\
                                 • Determine non-response or loss of response to medical therapy quickly and modify treatment, for example with accelerated step-up approach                               • Determine non-response or loss of response to medical therapy quickly and modify treatment accordingly
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ASUC, acute-severe ulcerative colitis; CD, Crohn's disease; CRP, C-reactive protein; GI, gastrointestinal; IBD, inflammatory bowel disease; STRIDE, Selecting Therapeutic Targets in Inflammatory Bowel Disease; UC, ulcerative colitis.

3. Adopting the 5S Principles in IBD Management {#s3}
===============================================

3.1. Staging the disease {#s4}
------------------------

IBD is heterogeneous in nature, so each patient has an individual disease profile. The first step in managing patients with IBD in clinical practice is to stage the disease. This includes defining the location of the disease and determining whether complications \[such as extra-intestinal manifestations\] are present, along with considering other factors that are specific to Crohn's disease or ulcerative colitis.

### 3.1.1. Crohn's disease {#s5}

In patients with Crohn's disease, recommendations on staging the disease are provided by the Montreal Classification.^[@CIT0002]^ This involves defining the disease location \[ie ileal, colonic, or ileocolonic\], including whether there is upper gastrointestinal involvement, determining disease behaviour, and assessing if perianal disease is present.^[@CIT0002]^ Other factors to consider include the patient's age, disease duration \[ie whether it is early- or late-onset disease\], and the dominant behaviour since diagnosis \[ie whether it is inflammatory, stricturing, or penetrating disease\].

### 3.1.2. Ulcerative colitis {#s6}

In patients with ulcerative colitis, the Montreal Classification focuses on determining disease extent and the severity of individual acute relapses.^[@CIT0002]^ In line with the Montreal classification, we recommend that staging should also involve defining the disease location \[proctitis, left-sided, or extensive disease\] and disease severity \[mild, moderate, severe, or acute-severe disease\]. However, staging should also consider risk markers for disease course such as biological disease severity (based on C-reactive protein \[CRP\] and haemoglobin levels, and endoscopy) at initial presentation.

3.2. Stratifying patients {#s7}
-------------------------

Following disease staging, patients with IBD should be stratified based on risk factors and predictors of disease progression. As part of an IBD Ahead initiative, predictors of long-term IBD prognosis were identified via a comprehensive literature review. This enabled summary statements to be developed which outlined demographic and clinical features that could be used to help guide the clinician in identifying patients at higher risk for disease complications at diagnosis and throughout the disease course.^[@CIT0003]^

### 3.2.1. Crohn's disease {#s8}

Patient stratification in Crohn's disease is based on the presence or absence of poor prognosis factors at diagnosis, such as extensive small bowel disease, severe upper gastrointestinal disease, severe rectal disease, complex perianal disease, early stricturing or penetrating disease, and deep colonic ulcers. Although some factors are associated with poor outcomes in Crohn's disease \[such as steroid dependency, colectomy, stenosis\],^[@CIT0004]^ there is no ideal definition of predictors of a severe or disabling disease course. Furthermore, the role of serological and genetic markers of poor prognosis remains to be determined, and there is currently a lack of validated biomarkers for an aggressive disease course.^[@CIT0005],[@CIT0009]^

### 3.2.2. Ulcerative colitis {#s9}

Patients with ulcerative colitis should be stratified based on risk factors that predict future surgery, including high stool frequency, severe endoscopic lesions, histological inflammation, elevated CRP, or anaemia. A simple index involving the extent of disease, CRP, and haemoglobin at diagnosis predicts the likelihood of admission with acute severe colitis over the next 3 years.^[@CIT0012]^

3.3. Setting treatment goals {#s10}
----------------------------

In recent years, IBD treatment goals have evolved from simple symptomatic remission towards achieving clinical and endoscopic, steroid-free, remission aimed at changing the course of disease. Achieving the selected treatment goal requires selection of the most appropriate treatment strategy \[eg conventional step care, accelerated step care, or an early top-down approach\].^[@CIT0013]^ A treat-to-target strategy in IBD, based on regular \[re-\]assessment of disease activity using objective outcome measures \[as well as patient-reported outcomes\] and the subsequent adjustment of therapy \[eg with rapid step up to biologic therapy in appropriate patients\], can potentially help patients achieve the selected treatment goal.^[@CIT0014],[@CIT0015]^ The Selecting Therapeutic Targets in Inflammatory Bowel Disease \[STRIDE\] programme developed evidence- and consensus-based recommendations for Crohn's disease and ulcerative colitis with regard to selecting goals as part of a treat-to-target strategy.^[@CIT0015]^ Prospective studies are now needed to determine how these targets can be used to change the disease course and improve patient quality of life.

3.4. Selecting appropriate treatment {#s11}
------------------------------------

The most appropriate IBD therapy should be selected based on an individual patient's disease stage, stratification, and selected treatment goal. Importantly, optimised IBD management should be based on a time-bound treatment strategy involving timely evaluation of treatment success and rapid step-up where required in appropriate patients.^[@CIT0016]^

Tailored use of the current IBD drug armamentarium (5-aminosalicylic acid \[5-ASA\], steroids, thiopurines, methotrexate, and biologics) can help deliver specific management goals and improve patient outcomes. Patients with potential poor prognosis \[ie presence of inflammation determined by imaging, elevated CRP/calprotectin; markers of poor prognosis\] may be considered for biologics \[after safety assessment: to exclude presence of tuberculosis or viral infections\]. Indeed, studies in patients with Crohn's disease suggest it is beneficial to start biologic therapy early \[ie before the disease has progressed\], with targeted early treatment potentially leading to more patients achieving and maintaining remission.^[@CIT0016],[@CIT0021]^ In both Crohn's disease and ulcerative colitis, anti-tumour necrosis factor \[TNF\] therapy is associated with steroid-free, clinical, and endoscopic remission as well as a reduced risk of surgery.^[@CIT0021]^ However, it is currently unclear whether biologics reduce disability and damage in IBD.

3.5. Supervising therapy {#s12}
------------------------

As part of a treat-to-target strategy, supervision of therapy using optimised monitoring can help improve management decisions in IBD. However, there is still a need to develop effective non-invasive monitoring techniques.^[@CIT0029]^

In symptomatic patients, monitoring enables the right treatment to be provided at the right time and optimised quickly, with non-response identified early and treatment modified accordingly. In asymptomatic and postoperative patients, this strategy enables appropriate maintenance therapy to be provided, monitoring for signs of relapse with pro-active management, and prevention of complications. For example, patients with asymptomatic Crohn's disease may have elevated CRP levels,^[@CIT0030]^ and thus benefit from further evaluation and closer monitoring to prevent complications and hospitalisation. The Post-Operative Crohn's Endoscopic Recurrence \[POCER\] study investigated whether early endoscopic monitoring with treatment step-up for endoscopic recurrence was superior to standard drug therapy alone in patients with Crohn's disease who had undergone intestinal resection.^[@CIT0031]^ Study findings indicated that treatment according to clinical risk of recurrence, with early colonoscopy \[at 6 months\] and treatment step-up, was better than conventional drug therapy alone in preventing postoperative Crohn's disease recurrence. The authors concluded that whereas clinical risk factors predicted disease recurrence, patients at low risk also needed close monitoring.

In managing non-response to therapy, it is important first to define the appropriate time window in which to assess non-response \[which is treatment-dependent\]. In patients treated with biologics, therapeutic drug monitoring can help inform whether the drug dose should be optimised or whether an alternative strategy needs to be considered \[ie switching within or out of drug class\]; however, therapeutic drug monitoring for biologics is not currently available in all countries. In patients treated with thiopurines, metabolite monitoring \[6-thioguanine nucleotides and 6-methylmercaptopurine\] can help determine why a patient is not responding to a standard dose of a thiopurine. This can help distinguish non-adherence, under-dosing, and thiopurine-resistant and thiopurine-refractory disease, to guide treatment decisions.^[@CIT0032]^

4. The 5C concept in IBD management {#s13}
===================================

The 5C Charter, which outlines the components of the 5C Concept, was established at the second IBD Expert Alliance meeting in Tokyo, Japan, in 2013, following comprehensive round-table discussions by key collaborators in the programme. During these sessions, it was evident that optimised management of patients with IBD \[based on the 5S Principles\] can be achieved most effectively within an optimised clinical care environment. Thus, the 5C Concept was conceived to provide guidance on the importance of optimising the clinical care setting in IBD management. The final components of the 5C Concept were agreed through group consensus and include the following categories: Comprehensive IBD care; Collaboration; Communication; Clinical nurse specialists; and Care pathways \[[Table 2](#T2){ref-type="table"}\]. Application of the 5C Concept in clinical practice was discussed further during subsequent Expert Alliance meetings, to allow ongoing sharing of best practice.

###### 

The 5C Concept in IBD clinical care

  Concept                                                     Use in clinical practice
  ----------------------------------------------------------- ------------------------------------------------------------------------------------------------------------
  Comprehensive IBD care                                      • Evaluate and monitor the disease using best techniques
  • Evaluate and manage complications                         
  • Specialist centres deliver specialist training            
  Collaboration                                               • Greater use of MDT meetings and networking
  • Collaborate with other specialists \[eg dermatologist\]   
  Communication                                               • Help patient to understand their disease and risk factors
  • Develop better patient education                          
  • Agree shared goals between physician and patient          
  Clinical nurse specialists                                  • Play a pivotal role in supporting patients and helping physicians to spend appropriate time with patient
  Care pathways                                               • Define patient-centred pathways so that care for patients may be rapid and seamless

IBD, inflammatory bowel disease; MDT, multidisciplinary team.

4.1. Comprehensive IBD care {#s14}
---------------------------

Effective management of patients with IBD, based on the 5S Principles, can be achieved within a framework of comprehensive IBD care. This should encompass effective disease evaluation and monitoring based on the best available techniques. Patients should be assessed for disease status at baseline using the following where available: blood biochemical testing, endoscopic findings, computed tomography scanning, and magnetic resonance imaging, using standardised reporting indices where possible. Based on baseline results, patients should receive appropriate treatment, during which monitoring using biomarkers and imaging should be implemented to inform further management decisions. This can all be achieved within an environment that is governed by recognised standards of care and auditing processes.

4.2. Collaboration {#s15}
------------------

The pattern and complexity of IBD varies considerably across patients and even within the same patient over time.^[@CIT0033]^ Individuals normally require long-term clinical follow-up because of disease exacerbations and the risk of complications. This can necessitate extensive diagnostic procedures, as well as medical and surgical treatments, over the patient's lifetime. A multidisciplinary team \[MDT\] approach, which includes HCPs with complementary therapeutic skills and knowledge, can provide patients with an optimised management experience. Core team members should include a gastroenterologist, colorectal surgeon, radiologist, pathologist, IBD specialist nurse and dietitian, with access to named specialists when appropriate, including a hepatologist, psychologist or psychiatrist, primary care physician, rheumatologist, dermatologist, ophthalmologist, respiratory physician, and obstetrician.^[@CIT0034]^ A pharmacist can be useful in providing assistance with drug monitoring and assessment of adherence to therapy, which is often suboptimal in some patient groups such as adolescents and patients with depression.^[@CIT0035]^ Importantly, an effective MDT can help provide optimised IBD clinical care by defining a realistic diagnostic and therapeutic pathway tailored to an individual patient's needs, based on locally available professional, structural, and technological resources. The organisation of an MDT should include its remit, decision documentation, and communication with the patient.

4.3. Communication {#s16}
------------------

Given that IBD is a lifelong disease that affects key developmental and life events,^[@CIT0036]^ good communication between patients and HCPs is essential. Indeed, patients are faced with a growing amount of IBD information and an increasing number of available therapies. Furthermore, the benefit/risk profile of individual treatment strategies is often patient-specific. Therefore, patient engagement and involvement in the decision making process is very important. This can be achieved through effective communication between HCPs and patients, which helps to align the disease management approach and improves patients' understanding of their IBD. Educated patients are more likely to appreciate the importance of achieving and sustaining treatment goals, which can lead to better treatment compliance and persistence. Important aspects of communication include: reviewing symptoms and flare triggers; addressing queries on adherence; considering life stressors or events; reviewing and agreeing treatment goals; and reviewing treatment options \[including risks and benefits, and the consequences of not taking therapy or delaying the decision to start treatment\].

In support of effective communication, a meta-analysis of 127 studies in a variety of medical conditions showed that good HCP communication led to a significant improvement in patient adherence.^[@CIT0037]^ HCP communication skills training significantly increased patient adherence (odds ratio \[OR\]: 1.62); and pre-treatment assessment of perceived needs and concerns predicted subsequent adherence. Conversely, poor communication may result in physicians failing to understand issues that are important to patients, and underestimating the impact of IBD on all aspects of their patients\' lives, and lead to poor adherence.

4.4. Clinical nurse specialists {#s17}
-------------------------------

Clinical nurse specialists have a pivotal role in IBD management, supporting both patients and the MDT. Importantly, multidisciplinary care that includes the IBD nurse role is endorsed in guidelines.^[@CIT0038],[@CIT0039]^ IBD nurses can help support the physical, social, and psychological functioning of patients. They can help patients determine their unique meaning of health and illness, help patients determine their health goals \[considering their limitations and capabilities\], and identify actions alternative to standard of care when warranted. They are also essential in providing patients with tailored education and in connecting patients with other members of the MDT when required. On a broader level, IBD nurses may also educate other nurses through national and international media.

Use of standard protocols \[eg for biologics\] enables IBD nurses to provide consistent and safe patient management. This can be achieved through nurse-led clinics, nurse-led infusions, and telephone helplines, all of which improve patient care. Nurses can also use approved benefit/risk documents to further discuss medical options agreed between the patient and physician. Finally, IBD nurses have an important role in patient follow-up, where they may plan routine laboratory investigations and the timing of the next endoscopy, provide injection training, discuss the importance of adherence, review patient quality of life, and review laboratory assessments.

4.5. Care pathways {#s18}
------------------

Carefully developed IBD care pathways are a structured way of developing and implementing local protocols of care founded on evidence-based clinical guidelines; as such, they integrate clinical practice guidelines and consensus reports with local specialist knowledge and clinical standards. Care pathways can include predictors of disease course and response, treatment algorithms, monitoring algorithms, and treatment targets. They provide high-quality, streamlined care from the point of diagnosis onwards to ensure an optimised experience for patients with IBD. Care pathways also enable effective collaboration between MDT members, as well as overall clarity with regards to disease management, which improves patient engagement. In the REACT study, a care pathway using early combined immunosuppression led to a significant (hazard ratio \[HR\]: 0·73, 95% confidence interval \[CI\] 0·62--0·86; *P* = 0.0003) reduction in the composite rate of major adverse outcomes \[occurrence of surgery, hospital admission, or serious disease-related complications\] compared with conventional management practices in patients with Crohn's disease.^[@CIT0040]^

5. Implementing the 5C concept and 5S principles in clinical practice {#s19}
=====================================================================

Implementation of agreed best-practice strategies is essential to eliminate variability in patient care across regions and countries. To achieve this, it is important that each institution develop its own structured initiative to help deliver consistent IBD management. The 5C Concept and 5S Principles provide institutions with structured recommendations on organising the clinical care setting and developing best-practice approaches in IBD management. Consideration and application of these two concepts could help HCPs optimise their IBD centres and collaborate more effectively with their MDT colleagues and patients, to provide improved IBD care in daily clinical practice. Of course, the 5C concept and 5S principles represent a model situation, and so each institution would need to tailor the recommendations to their situation depending on availability of resources and treatments, as well as standard protocols. Ultimately, the success of each implemented initiative would be determined by individual institutions measuring their key achievements in improving patient care. In this way, IBD care can be continually assessed and modified if necessary, to benefit patient outcomes.
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